Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.
about
Novel therapeutic targets for pancreatic cancerHER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical modelsERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1)Examination of HER3 targeting in cancer using monoclonal antibodiesCombining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodiesA critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma.Loss of FOXO1 promotes gastric tumour growth and metastasis through upregulation of human epidermal growth factor receptor 2/neu expression.Xiao-Ai-Ping, a TCM Injection, Enhances the Antigrowth Effects of Cisplatin on Lewis Lung Cancer Cells through Promoting the Infiltration and Function of CD8(+) T Lymphocytes.Cancer subclonal genetic architecture as a key to personalized medicine.EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo.Where does radioimmunotherapy fit in the management of breast cancer?The HER2 Signaling Network in Breast Cancer--Like a Spider in its Web.Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds.The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation.[The HER3/ERBB3 receptor: the dark side of the ERBB planet].Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV.
P2860
Q24564267-8DCB555D-E31E-493D-85D8-D2D2EA3EBF0FQ27853067-A5EE9E78-432F-4408-8657-B3F7AB49FAF4Q33772914-CA0D15BE-AAA8-4109-BBAE-7CB91E66C2ACQ35031462-E5F82E40-32F4-4F0C-B252-6E92AECB1B88Q35409548-8C791A8B-D68A-41DF-8327-869B928A19A5Q35682599-0B4C67A5-C0EE-4F98-B9B6-21EB62D03ED8Q35987242-58DE7AF5-D984-45F9-A9D7-6A06B767F4DBQ36287390-591AA41A-E442-4F6C-8CB3-C26F99864FD9Q37061399-27F35525-D54F-4ACE-9CF2-C84B98A74999Q37448116-B959F015-129F-4B7A-A41A-98EE6CFEBA86Q37474367-AF00F2DE-1E5F-4C59-960C-EA60A15C7366Q38125535-588DE585-3C7C-4392-81B0-6C63D58822AAQ38302045-F2223A0D-005B-4EB4-9F02-22C3136EF340Q38623361-5766DA47-68C7-4F31-A4AB-454BA6B95978Q38929801-A48F6310-AD5A-47B7-BDBF-237146E57F25Q41667670-0BD5B996-80F6-4521-B9E1-BB68A219BAAAQ54266767-D44400B6-D707-46FC-9261-E78D87467A47Q55000376-116262B7-E167-4C2E-941B-AF2A7EDB8EE3
P2860
Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Anti-HER3 domain 1 and 3 antib ...... AP, and FoxO1 phosphorylation.
@ast
Anti-HER3 domain 1 and 3 antib ...... AP, and FoxO1 phosphorylation.
@en
type
label
Anti-HER3 domain 1 and 3 antib ...... AP, and FoxO1 phosphorylation.
@ast
Anti-HER3 domain 1 and 3 antib ...... AP, and FoxO1 phosphorylation.
@en
prefLabel
Anti-HER3 domain 1 and 3 antib ...... AP, and FoxO1 phosphorylation.
@ast
Anti-HER3 domain 1 and 3 antib ...... AP, and FoxO1 phosphorylation.
@en
P2093
P2860
P50
P356
P1433
P1476
Anti-HER3 domain 1 and 3 antib ...... IAP, and FoxO1 phosphorylation
@en
P2093
André Pèlegrin
Bruno Robert
Christel Larbouret
Christophe Le Clorennec
Gaelle Thomas
Hakim Kharrat
Khalil Bouayadi
Marta Jarlier
Nadège Gaborit
P2860
P304
P356
10.1593/NEO.121960
P577
2013-03-01T00:00:00Z